Skip to content
Baltimore News Journal – Lifestyle
Author:
Rezera Inc.
Rezera Announces Late-Breaking Presentation of RESOLVE-1 Clinical Data at the American Heart Association (AHA) Scientific Sessions 2026
September 23, 2026
Rezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study Investigating the Role of Inflammation in Patients with Peripheral Artery Disease
September 16, 2026
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
September 9, 2026
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
September 9, 2026